Document is current

Article History

Received: 7 January 2026

Accepted: 2 March 2026

First Online: 19 March 2026

Declarations

:

: Gil Yosipovitch has received funding/grants from Celldex, Eli Lilly, Escient Health, Kiniksa, Novartis, Pfizer, Regeneron, and Sanofi; has received consulting support from AbbVie, Arcutis, Eli Lilly, Escient Health, Galderma, Kamari, Kiniksa, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, Trevi Therapeutics, and Vifor; has received honoraria from Maruho; has participated in advisory boards for AbbVie, Eli Lilly, Escient Health, Galderma, GSK, Kamari, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, Trevi Therapeutics, and Vifor; and holds patents for Topical Acetaminophen Formulations for Itch Relief. Gil Yosipovitch is an Editorial Board member of Dermatology and Therapy. Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Giselle Mosnaim serves on the AAAAI/ACAAI JTFPP Steering Committee; receives current research grant support from Areteia, Celldex, Genentech, GlaxoSmithKline, Incyte, Merck, Novartis, Regeneron, Sanofi, and Teva; and receives consulting, advisory board, and/or speaking fees from Chiesi, Genentech, Jasper, Novartis, Regeneron, Sanofi, and Teva. Christine-Elke Ortmann and El-Djouher Martzloff are employees of Novartis Pharma AG, Basel, Switzerland. Nicole Griswold, Jane Mast, and Jonathan Rodrigues are employees of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Jason E. Hawkes has served as an advisor, consultant, speaker, investigator, and/or medical board member for AbbVie, Acelyrin, Allakos, Alumis, Amgen, Apogee, Arcutis, Boehringer Ingelheim, Blueprint Medicines, Bristol Myers Squibb, Celldex, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, National Psoriasis Foundation, Novartis, Oruka, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB.

: This study was designed and will be implemented, executed, and reported in accordance with consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) international ethical guidelines, applicable International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Tripartite Guidelines for Good Clinical Practice (GCP), and other applicable local regulations. All study patients will be required to sign a statement of informed consent.